The T Rex gobbles up his Essential Fatty Acids! ]
Information obtained from EFAMOL Inc.
World Leaders in Research of Essentional Fatty Acids
[NUTRICIA now owns Efamol]
Leaders in Nutritional Health
Native North Americans to the World
For many who know the benefits of this legendary plant, Efamol
is synonymous with Evening Primrose Oil (EPO), a rich source of
essential fatty acids currently being studied in medical centers
worldwide for their impact on human health. Derived from the term
Essential Fatty Acid MOLecule, the name Efamol demonstrates the
company's ongoing commitment to researching the impact of essential
fatty acids and other naturally delivered products on human biology
and to developing nutraceutical products that improve the quality
of peoples' lives.
company's story began when Dr. David Horrobin was professor of
medicine at the University of Montreal. While researching the
hormone prolactin's regulation of prostaglandin E1 (PGEI), a healthful
substance the body breaks down too quickly, Dr. Horrobin identified
a precursor chemical called gamma linolenic acid (GLA). GLA, Dr.
Horrobin discovered, could be used to make PGEI and was readily
available in the seed of the Evening Primrose plant.
1977, Dr. Horrobin and Sherri Clarkson founded the Efamol Company
in Montreal, Canada to commercialize his research into GLA. The
following year, the company joined Agricultural Holdings, a large
United Kingdom manufacturing company, moved to East London and
began making its first products. In 1981, the company's Canadian
division, Efamol Research, Inc. moved to Nova Scotia, and the
manufacturing division, Efamol Ltd., relocated to Guildford, England.
In 1985, Efamol Ltd. changed its registered corporate name from
Efamol Holdings to Scotia Holdings, PLC, but maintained the Efamol
brand name for its wide range of nutritional products.
Efamol Nutraceuticals are among the best-selling essential fatty
acid products in the world and Efamol Research, Inc. is the principal
biomedical research resource for the entire Scotia/Efamol organization.
Scotia Holdings, Efamol Ltd's parent company, is listed on the
London Stock Exchange and maintains three principal divisions:
Scotia Pharmaceuticals, which manufactures, markets and registers
pharmaceutical products; Efamol Ltd., which produces and distributes
nutritional products; and Scotia Drug Discovery, the company's
R&D resource for its ongoing development of nutritional and
pharmaceutical products. In Canada, the company operates under
the name Efamol Research, Inc., but is registered as Scotia Pharmaceuticals
(Canada) Limited to maintain a uniform identity.
Efamol | Leaders
in EFAs | Important EFAs ]